Healthcare / Drug Manufacturers - Specialty & GenericHKSE
$9.16
+0.01 (+0.11%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 19%
FCF escenarios
weak_data · normalized FCF $-2.6M · quality 48.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
69/100
B
Piotroski
7/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$2.2B
P/E
9.3x
↓EV/EBITDA
42.0x
↑ROE
11.6%
↑Gross Margin
14.4%
↓Debt/Equity
0.17
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+49.9%
FCF CAGR
—
FCF margin
5.2%
FCF / Net income
0.87x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $535.9M · net income $32.1M · FCF $28.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $535.9M | $535.9M | $307.7M | $174.0M | $159.2M |
| Net Income | $32.1M | $32.1M | $11.2M | $2.6M | $-6.7M |
| EBITDA | $55.4M | $55.4M | $26.4M | $11.3M | $5.2M |
| EPS | 0.13 | 0.13 | 0.04 | 0.01 | -0.03 |
| Gross Margin | 14.4% | 14.4% | 15.9% | 17.3% | 24.6% |
| Operating Margin | 7.6% | 7.6% | 4.2% | -1.9% | 3.7% |
| Net Margin | 6.0% | 6.0% | 3.6% | 1.5% | -4.2% |
| Balance Sheet | |||||
| Debt/Equity | 0.17 | 0.17 | 0.29 | 0.34 | 0.21 |
| Current Ratio | 1.57 | 1.57 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $28.0M | $28.0M | $-2.6M | $-27.2M | $-10.4M |
| Returns | |||||
| ROE | 11.6% | 11.6% | 4.8% | 1.1% | -2.9% |
| Valuation | |||||
| P/E | 9.25 | 9.25 | 35.60 | 87.13 | — |
| EV/EBITDA | 42.03 | 42.03 | 16.47 | 23.34 | 36.85 |
| P/B | 8.37 | 8.37 | 1.69 | 0.98 | 0.75 |
| Growth & Yield | |||||
| Revenue Growth | 74.1% | 74.1% | 76.9% | 9.3% | — |
| EPS Growth | 186.8% | 186.8% | 336.6% | 138.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
85.9%
EPS terminal req.
$0.81
Spread vs growth
100.9%
5Y implied EPS CAGR
50.7%
EPS terminal req.
$0.98
Spread vs growth
136.1%
10Y implied EPS CAGR
28.8%
EPS terminal req.
$1.58
Spread vs growth
158.1%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+400.5%
Start / end P/E
41.5x → 72.4x
EPS bridge
0.04 → 0.13
Residual
+139.2%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.